FASgen, New Discovery in Obesity Research

Dec. 21, 2007 - FASgen is pleased to report the publication of important new research results in the obesity field using FAS89B, one of the Company's proprietary compounds. FASgen is a leader in the field of research into selective inhibition of fatty acid synthase (FASi), and has conducted extensive research in the area of metabolic disease disorders, specifically for the treatment of obesity and fatty liver disease... FASgen's Press Release -

Genaera, Positive Phase 1 Trodusquemine (MSI-1436)

October 25th, 2007 -- Genaera Corporation (NASDAQ: GENR) is providing the following summary of highlights related to the successful first Phase 1 study of trodusquemine and additional preclinical data expanding the support for selectivity and specificity of the drug in preclinical models from the North American Association for the Study of Obesity (NAASO) Annual Meeting in New Orleans... Genaera's Press Release -

Orexigen Therapeutics, Phase IIb Trial of Empatic to Treat Obesity

Oct 21, 2007 - Orexigen Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders including obesity, announced detailed results at the 24 week primary endpoint of its Phase IIb trial of Empatic, one of its two obesity drug candidates*... Orexigen's Press Release-

VIVUS, Qnexa Quality of Life Data

Oct. 22, 2007--VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, announced that Dr. Kishore Gadde presented the positive results of the Quality of Life data collected during the phase 2 clinical trial of Qnexa at the North America Association of the Study of Obesity (NAASO) 2007 Annual Scientific Meeting in New Orleans, LA... VIVUS' Press Release-

Orexigen Therapeutics, Third Phase III Trial for Contrave to Treat Obesity

Oct 17, 2007 - Orexigen™ Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders including obesity, announced the initiation of the third trial in its Phase III clinical trial program for its lead product candidate Contrave™ as a treatment for obesity. The program includes a set of four Phase III trials evaluating a variety of obesity-related outcome measures... Orexigen Therapeutics' Press Release-

AstraZeneca, Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms

October 16, 2007 - The link between gastroesophageal reflux disease (GERD) and obesity has long been established, but healthcare professionals have had little guidance as to whether obese patients with GERD* should be treated differently than normal-weight patients with GERD. Two studies about obesity and its relationship to GERD were presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting this week... AstraZeneca's Press Release-

Sound Health Solutions, Support for Microsoft HealthVault

Oct. 4, 2007 - Sound Health Solutions, Inc. today announced support for HealthVault, Microsoft Corporation's newly launched consumer-health platform that provides consumers with the ability to search, store and connect their health information, simplifying management of their health and wellness... Sound Health Solutions, Inc. offers highly successful, multi-disciplinary weight management programs designed by physicians.... Sound Health Solutions' Press Release-

GSK , OTC weight loss product In Europe

Tuesday 2 October 2007 - GlaxoSmithKline (GSK) announced its marketing application for non-prescription orlistat 60mg for weight loss has been accepted for review by the European Agency for the Evaluation of Medicinal Products (EMEA)...Alli is the only FDA-approved weight-loss product available to consumers without a prescription, and it is the first clinically-proven over-the-counter product to be combined with a comprehensive support programme... GlaxoSmithKline's Press Release -

Nastech Pharmaceutical , Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity

Oct. 1 , 2007 - Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced the start of a Phase 2 clinical trial evaluating the Company's PYY3-36 Nasal Spray in obese patients. The study will enroll approximately 500 obese patients for a six-month, randomized, placebo-controlled dose ranging study with weight loss as the primary endpoint... Nastech Pharmaceutical's Press Release -

Ethicon Endo-Surgery, REALIZE™ Adjustable Gastric Band For Morbid Obesity

September 28, 2007– Ethicon Endo-Surgery, Inc. announced the U.S. Food and Drug Administration (FDA) approved for marketing the REALIZE™ Adjustable Gastric Band, a surgical implant for weight reduction and improvement in obesity-related health conditions, such as type-2 diabetes, in individuals suffering from morbid obesity... Ethicon's Press Release -

METABOLEX , PHASE 2 TRIAL OF MBX-802, Study Will Assess Drug’s Benefit, Alone and with Lipitor®, in Overweight or Obese Patients

September 25, 2007 - Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced that it has begun a 180-patient Phase 2 trial of MBX-8025 in overweight or obese patients with high cholesterol and triglycerides to assess the drug’s effect on dyslipidemia, insulin-resistance and obesity... Metabolex's Press release -

DOV Pharmaceutical, Significant Body Weight and BMI Reductions in Drug-Compliant Subjects in Phase Ib Clinical Study

Sept. 25 , 2007- DOV Pharmaceutical, Inc. announced additional Phase Ib results for DOV 21,947, its lead triple reuptake inhibitor ("TRIP") for the treatment of depression and obesity... DOV Pharmaceutical's Press Release -

Orexigen, positive results in two Phase I clinical trials of naltrexone, key component of the Company's lead product candidate for obesity, Contrave

Sep 25, 2007 - Orexigen™ Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders including obesity, announced positive results in two Phase I clinical trials of its proprietary sustained release (SR) formulation of naltrexone. Orexigen has developed this proprietary SR formulation of naltrexone with the objective of improving tolerability by modifying the pharmacokinetics of immediate release (IR) naltrexone. Naltrexone is a key component of the Company's lead product candidate for obesity, Contrave, which is currently being studied in Phase III clinical trials... Orexigen's Press Release -

Metabolex and Astellas, to identify potential drug candidates by examining genes associated with insulin resistance and obesity

September 19, 2007 / Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced today that Astellas Pharma Inc. has begun high-throughput screening against an additional target from Metabolex’s proprietary human gene database. Astellas is working to identify potential drug candidates by examining genes associated with insulin resistance and obesity... Metabolex's Press Release -

Arena Pharmaceuticals, Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review

Sept 11, 2007 - Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced that an independent Echocardiographic Data Safety Monitoring Board (the Board or EDSMB) found no reason to stop the ongoing pivotal Phase 3 trial, BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management). The BLOOM trial is evaluating the efficacy and safety of lorcaserin hydrochloride for the treatment of obesity... Arena Pharmaceuticals' Press release -

Salugen , GenoTrim - a DNA Customized Nutritional Solution for Weight Management

Sept. 11, 2007 - Salugen, Inc., a personalized health and wellness company, announced the launch of GenoTrim, a DNA-based nutritional solution for weight management*. Attempts to achieve a healthy weight through both standard weight reduction strategies and numerous "gimmicks" have proven unsuccessful for the 58 million overweight individuals in the U.S. GenoTrim uniquely identifies specific genetic factors affecting hunger, metabolism and body composition that may contribute to the weight challenges of many of these individuals. Salugen's Press Release -
* These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Genaera, Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)

September 10th, 2007 -- Genaera Corporation (NASDAQ: GENR) announced the formation of its Trodusquemine Scientific Advisory Board (the “SAB”), consisting of leading experts in the areas of obesity, diabetes and metabolic disorders, to provide guidance on the development of trodusquemine (MSI-1436), the Company’s novel small molecule drug candidate for the treatment of obesity and type 2 diabetes... Genaera's Press Release -

an obesity blog

The aim of the Blog "ObePosition" is to share information found in life sciences companies websites which could be interesting to follow new medical devices, pharmaceuticals, treatments, clinical trials for obesity.